Browse > Article
http://dx.doi.org/10.6116/kjh.2015.30.3.35.

The improving effect of Zizyphus jujube on dextran sulfate sodium-induced colitis in mice  

Myung, Noh-Yil (Department of Oriental Medicine and Healthcare, Wonkwang Digital University)
Publication Information
The Korea Journal of Herbology / v.30, no.3, 2015 , pp. 35-40 More about this Journal
Abstract
Objectives : Zizyphus jujube (ZJ) has been used as a traditional medicine for various diseases. However, the inhibitory effect of ZJ on intestinal inflammation has not been fully understood, yet. The aim of this study is to investigate anti-colitis activity of ZJ in dextran sulfate sodium (DSS)-induced colitis mouse model. Methods : To investigate the protective effects of ZJ,the colitis mice were induced by drinking water containing 5% DSS for 7 days. Mice were randomized into groups receiving ZJ (500 mg/kg), sulfasalazine (SFZ) (150 mg/kg) as a positive control, or water as a negative control. We assayed the effects of ZJ on DSS-induced the clinical signs, measuring weight loss, colon length and disease activity index (DAI). Additionally, to find a possible explanation for the anti-inflammatory effects of ZJ, we evaluated the effects of ZJ on the production of prostaglandin $E_2$ ($PGE_2$) and expression of cyclooxygenase (COX)-2 in colitis tissue. Results : The results showed that mice treated with DSS showed considerable clinical signs, including weight loss, and reduced colon length. However, administration of ZJ significantly reduced the weight loss, shortens colon length, and improved DAI as clinical symptoms. Moreover, ZJ inhibited the $PGE_2$ production and COX-2 expression levels in DSS-treated colon tissues. Conclusions : Collectively, the findings of this study provide us with novel insights into the pharmacological actions of ZJ as a potential molecule for use in the treatment of intestinal inflammation including ulcerative colitis.
Keywords
Zizyphus jujube; Ulcerative Colitis; Dextran Sulfate Sodium; prostaglandin $E_2$; Cyclooxygenase-2;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Danese S, Sans M, Fiocchi C. Inflammatory bowel disease; the role of environmental factors. Autoimmun Rev. 2004 ; 3(5) : 394–400.   DOI   ScienceOn
2 Han BH, Park MH, Han YN. Sedative activity of aporphine and cyclopeptide alkaoids isolated from the seed of Zizyphus vulgaris var. Spinosus, and the fruits and stem bark of Zizyphus jujuba var. Inermis in mice. J Pharm Soc Korea. 1993 ; 37(2) : 143–8.
3 Heo HJ, Park YJ, Suh YM, Choi SJ, Kim MJ, Cho HY, Chang YJ, Hong B, Kim HK, Kim E, Kim CJ, Kim BG, Shin DH. Effects of oleamide on choline acetyltransferase and cognitive activities. Biosci Biotechnol Biochem. 2003 ; 67(6) : 1284–91.   DOI   ScienceOn
4 Huang YL, Yen GC, Sheu F, Chau CF. Effects of water-soluble carbohydrate concentrate from Chinese jujube on different intestinal and fecal indices. J Agric Food Chem. 2008 ; 56(5) : 1734–9.   DOI   ScienceOn
5 Naftali T, Feingelernt H, Lesin Y, Rauchwarger A, Konikoff FM. Ziziphus jujuba extract for the treatment of chronic idiopathic constipation: a controlled clinical trial. Digestion. 2008;78(4):224–8.   DOI   ScienceOn
6 Hyams JS. Inflammatory bowel disease. Pediatr Rev. 2000 ; 21(9) : 291–5.   DOI
7 Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002 ; 15(1) : 79–94.   DOI
8 Lichtenstein GR, Rutgeerts P. Inflamm Bowel Dis. 2010 ; 16(2) : 338–46.   DOI   ScienceOn
9 Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev. 2004 ; 3(5) : 394–400.   DOI   ScienceOn
10 Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R, Xia B, Kuipers EJ, van der Woude CJ. Disease-related expression of the IL-6/STAT3/SOCS3 signaling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut. 2010 ; 59(2) : 227–35.   DOI   ScienceOn
11 Agoff SN, Brentnall TA, Crispin DA, Taylor SL, Raaka S, Haggitt RC, Reed MW, Afonina IA, Rabinovitch PS, Stevens AC, Feng Z, Bronner MP. The role of cyclooxygenase-2 in ulcerative colitis-associated neoplasia. Am J Pathol. 2000 ; 157(3) : 737–45.   DOI   ScienceOn
12 Roberts PJ, Morgan K, Miller R, Hunter JO, Middleton SJ. Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut. 2001 ; 48(4) : 468–72.   DOI
13 Ishiguro K, Ando T, Maeda O, Hasegawa M, Kadomatsu K, Ohmiya N, Niwa Y, Xavier R, Goto H. Paeonolattenuates TNBS-induced colitis by inhibiting NF-B and STAT1 transactivation. Toxicol Appl Pharmacol. 2006 ; 217(1) : 35–42.   DOI   ScienceOn
14 Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, Jung SA, Kim WH, Lee HY, IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Korean J Gastroenterol. 2012 ; 59(2) : 118–40.   DOI
15 Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. Novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990 ; 98(3) : 694–702.   DOI
16 Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002 ; 15(1) : 79–94.   DOI
17 Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000 ; 51 : 289–98.   DOI   ScienceOn
18 Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 1993 ; 38(9) : 1722–34.   DOI
19 Domènech E. Inflammatory bowel disease: current therapeutic options. Digestion. 2006 ; 73(1) : 67–76.   DOI   ScienceOn
20 Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993 ; 69(2) : 238–49.
21 Hendel J, Nielsen OH. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am J Gastroenterol. 1997 ; 92(7) : 1170–3.
22 Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004 ; 10(4) : 352–6.   DOI   ScienceOn